Clene Announces Registered Direct Offering of Over $28 Million

Core Viewpoint - Clene Inc. has announced a registered direct offering priced above market, raising over $28 million from new and existing investors to support its clinical-stage biopharmaceutical efforts in treating neurodegenerative diseases, particularly ALS and MS [1][2][3] Financing Details - The offering includes an oversubscribed registered direct offering to new, existing, and insider investors, with an initial financing tranche of over $6 million expected to fund operations into Q3 2026 [3] - Two additional financing tranches totaling over $22 million are contingent on the acceptance and approval of the New Drug Application (NDA) by the FDA, providing sufficient capital into early 2027 for potential commercialization of CNM-Au8 in ALS [3] - The gross proceeds from the offering are expected to be approximately $28 million, with BTIG, LLC acting as the sole placement agent [7] Warrant Details - The offering includes Series A Warrants and Series B Warrants, both with an initial exercise price of $6.00 per share, which can increase based on specific conditions related to the company's stock price and FDA announcements [4][5][6] - The potential gross proceeds from the exercise of the Series A Warrants total approximately $6.7 million, while the Series B Warrants could generate around $15.6 million, expected to fund commercialization efforts [5][6] Company Overview - Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ALS, Parkinson's disease, and MS [10] - CNM-Au8 is an investigational therapy designed to enhance neuronal health by increasing energy production and reducing oxidative stress [11]